DNAprint Genomics (DNAG)

[worktoplay]

Of course, the other interesting thing about that PR (especially considering the recent arguments of our resident amphibian):

About Biofrontera AG

Biofrontera is aiming to become a specialty pharma business, initially in the field of dermatology, with internal research capacity to extend its drug pipeline. Major shareholders of Biofrontera include Heidelberg Innovation and the 3i group. DNAPrint genomics Inc., a genomics-based company based in Sarasota, FL, recently also agreed to acquire a significant stake in Biofrontera.

http://www.biofrontera.com/

About InterPharmaLink

InterPharmaLink is a professional healthcare management consulting firm. The emphasis is on initiating and managing business transactions in the areas of late-stage development projects, in-market products and business development for the pharmaceutical industry.

CONTACT: Anke zur Muhlen, Corporate Communication, Biofronters AG,+011-49-0-214-87632-22, or +011-49-0-214-87632-90; or Richard Gabriel, CEO andPresident, DNAPrint™ genomics, Inc., [phone]

Interesting. Biofrontera puts out a PR announcing the in-licensing of a new Stage II drug, and they list Biofrontera Corporate Communications OR Richard Gabriel, DNAPrint genomics as the contacts.

Later,
W2P